Johnson & Johnson Innovative Medicine — Supplies expense remained flat by 0.0% to $25.00M in Q4 2024 compared to the prior quarter. Year-over-year, this metric declined by 85.7%, from $175.00M to $25.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase relative to revenue may signal rising input costs or manufacturing inefficiencies, while a decrease suggests improved cost management.
This represents the direct costs associated with raw materials, consumables, and other supplies used in the production a...
Comparable to cost of goods sold (COGS) components in other pharmaceutical manufacturing segments.
jnj_segment_innovative_medicine_supplies_expense| Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $800.00M | $175.00M | $175.00M | $175.00M | $175.00M | $25.00M | $25.00M | $25.00M | $25.00M |
| QoQ Change | — | -78.1% | +0.0% | +0.0% | +0.0% | -85.7% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | -78.1% | -85.7% | -85.7% | -85.7% | -85.7% |
We use cookies for analytics. See our Privacy and Cookie Policy.